BAYRY +17%: Supreme Court Clears the Roundup Overhang
Bayer's +16.98% session — the stock's best day in years — followed a US Supreme Court decision sharply curtailing plaintiffs' ability to pursue Roundup cancer claims under state tort law, materially reducing the legal liability discount that has suppressed BAYRY's valuation for most of the past decade. The fundamental question is whether the ruling resolves the multi-billion litigation reserve in full or merely pauses future claim accumulation — the distinction determines how much of the +17% is a permanent re-rating versus short-covering exhaustion. Sell-side PT distributions have not been updated for the ruling; expect analyst notes Monday to set the short-term ceiling for follow-through.
Read at DW Business Germany ↗